logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Unprecedented response rates seen with nivolumab+ipilimumab in recurrent/metastatic cervical cancer

Combining two types of immune checkpoint inhibitors yields unusually high response rates and prolonged survival in Checkmate 358.